Leuprorelin (Prostap®)
A Voluntary Ex-Ante Transparency (VEAT) Notice
by THE COMMON SERVICES AGENCY (MORE COMMONLY KNOWN AS NHS NATIONAL SERVICES SCOTLAND) (NSS)
- Source
- Find a Tender
- Type
- Framework (Supply)
- Duration
- not specified
- Value
- £3M
- Sector
- HEALTH
- Published
- 05 Nov 2025
- Delivery
- not specified
- Deadline
- n/a
Related Terms
Location
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act
2 buyers
- NHS National Services Scotland NSS Edinburgh
1 supplier
- Takeda London
Description
Supply of Leuprorelin (Prostap®) to NHS Scotland.
Total Quantity or Scope
The Authority has awarded this framework as a single supplier framework per line to one (1) Framework Participant. II.2.11) Information about option.
Award Detail
| 1 | Takeda (London)
|
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
Legal Justification
The patent for Leuprorelin (Prostap®) expired in June 2023, there is no known competition that has entered the UK market place and there is none anticipated for initial duration of the framework agreement.
Other Information
The total value in Sections II.1.7 and V.2.4 refers to the fourteen (14) months initial period with the option to extend by up to a total period of thirty four (34) months. NOTE: To register your interest in this notice and obtain any additional information please visit the Public Contracts Scotland Web Site at https://www.publiccontractsscotland.gov.uk/Search/Search_Switch.aspx?ID=814626. (SC Ref:814626)
Reference
- FTS 071242-2025